Research area · Neuropeptide research

Semax and Selank research, sorted

Semax and Selank are two short peptides people often ask about. In July 2026 an FDA advisory committee voted to recommend Semax for compounding. Selank was not on that committee's agenda.

  • Evidence grade or review status for every compound
  • Sources listed on every page
  • US and sport status, dated
2 compoundsGuides published
Updated Nov 2026Dated on every page
SEMAX SELANK
The research so far

What has been studied

In July 2026 the FDA's compounding advisory committee voted to recommend adding Semax to the 503A bulks list, against FDA staff's proposal. The October 2026 HHS policy covers it under ten conditions. An advisory vote is not a rule, and the policy is not an approval. [1] [4] [2]

Selank was not among the peptides the FDA's committee reviewed in July 2026 or the six covered by the HHS policy. FDA lists it among substances formerly in Category 2 whose nominations were withdrawn (list current 22 April 2026). [1] [2] [5]

What the research does not show

Saying what we don't know is part of the evidence.

What Semax or Selank do in people. This page makes no statement about effects; the Semax and Selank guides set out the human studies, their design and their limits.

Where it stands legally

As of November 2026. See the full tracker and the changelog.

CompoundFDA approval503A compounding (2026)WADA (2026 List)
SemaxNot approvedFDA advisory committee voted for listing (Jul); HHS enforcement-discretion policy (Oct); no rule yetCheck with your anti-doping body
SelankNot approvedFormerly FDA Category 2; nomination withdrawn (FDA list, current 22 Apr 2026); not on the July 2026 committee agenda or in the October HHS policyCheck with your anti-doping body

Worth knowing

Research use only

None of the compounds on this page is an FDA-approved medicine. Nothing on this page is medical advice or describes use in people.

What research use only means

No doses, ever

We publish no doses, protocols, or cycles for people, on any page.

Why we publish no doses

How we grade evidence

Grades follow study design: cell and animal studies (preclinical), small human studies, then controlled human trials, with approval tracked separately. A grade is not a promise of any effect.

Evidence grades

Questions people ask

Is Semax approved in the US?

No. The FDA has not approved it.

Are Semax and Selank allowed in sport?

Check with your anti-doping body. Our sport page explains how WADA's S0 class covers non-approved substances.

Sources

  1. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting page, 23–24 July 2026: agenda, voting questions and FDA briefing (no minutes posted as of 17 November 2026). www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
  2. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, 28 Oct 2026. www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf
  3. World Anti-Doping Agency. Prohibited List 2026 (in force 1 January 2026) and 2027 (in force 1 January 2027). www.wada-ama.org/en/prohibited-list
  4. U.S. Department of Health and Human Services. Enforcement discretion policy, Appendix B: peptide identities and justifications, October 2026 (records the July 2026 committee outcome for each of the six peptides). www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
  5. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of 22 April 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

Start with the evidence

Every page sourced and dated, including what the research does not show.

Open the research library
Written by 6AM Research. Drafted with AI from published studies, trial registries, and regulator documents, plus press reports where marked. Every page lists its sources and is dated. Editorial policy · Corrections
Education only. Nothing here is medical advice or describes use in people. Research use only